中南大学 Zuo Xiao Cong

Language : English

Zuo Xiao Cong

Home

Journal Publications

Research Projects

Books

Patents

Teaching

Honors and Awards

Recommended Ph.D.Supervisor
Recommended MA Supervisor

MOBILE Version

Journal Publications

Current position: Home > Journal Publications

[21]尹文俊, 陈林华, 杨慧琴.两种造影剂致老年患者造影剂肾病风险比较.医药导报, 2021
[22]Cui, C (Cui, Cheng), XB (Li, Xiaobei), Liang, H (Liang, Hao), Hou, Z (Hou, Zhe), Tu, SQ (Tu, Siqi), Dong, ZQ (Dong, Zhongqi), Yao, XT (Yao, Xueting), M (Zhang, Miao), Zhang, X (Zhang, Xuan), Li, HY (Li, Haiyan), Liu, DY (Liu, Dongyang).Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients.BIOPHARMACEUTICS & DRUG DISPOSITION, 2021
[23]Hu, C (Hu, Can), G (Zhou, Ge), Liu, K (Liu, Kun), Yin, WJ (Yin, Wenjun), Zhou, LY (Zhou, Lingyun), Wang, JL (Wang, Jianglin), Chen, LH (Chen, Linhua), Zuo, SR (Zuo, Shanru), Xie, YL (Xie, Yueliang).CaMKII as a key regulator of contrast-induced nephropathy through mPTP opening in HK-2 cells.CELLULAR SIGNALLING, 2020
[24]汪江林, 周凌云, 尹文俊, 李岱阳, 胡灿.基于倾向性匹配法评价丹红注射液预防造影剂诱导的急性肾损伤的临床效果.中南大学学报(医学版), 2020
[25]Zhou, LY (Zhou, Ling-Yun), Yin, WJ (Yin, Wen-jun), Wang, JL (Wang, Jiang-lin), Hu, C (Hu, Can), Liu, K (Liu, Kun), Wen, J (Wen, Juan), Peng, LP (Peng, Li-ping).A Novel Laboratory-Based Model to Predict the Presence of Obstructive Coronary Artery Disease Comparison to Coronary Artery Disease Consortium 1/2 Score, Duke Clinical Score and Diamond-Forrester Score in China.INTERNATIONAL HEART JOURNAL, 2020
[26]谢悦良, 常果子, 彭向东, 刘亚妮, jiasujie, 李佐军, zhangbikui, 师少军.新型冠状病毒肺炎疫情下的医院药事管理应急预案.中南药学, 2020
[27]JL (Wang, Jiang-lin), Yin, WJ (Yin, Wen-jun), LY (Zhou, Ling-yun), Zhou, G (Zhou, Ge), Liu, K (Liu, Kun), Hu, C (Hu, Can), Wang, YF (Wang, Ya-feng).Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.CLINICAL RHEUMATOLOGY, 2020
[28]Yin, WJ (Yin, Wen-jun), LY (Zhou, Ling-yun), Li, DY (Li, Dai-yang), Xie, YL (Xie, Yue-liang), Wang, JL (Wang, Jiang-lin), Zuo, SR (Zuo, Shan-ru), Liu, K (Liu, Kun), Hu, C (Hu, Can), Zhou, G (Zhou, Ge), Chen, LH (Chen, Lin-hua), Yang, HQ (Yang, Hui-qing).Protective Effects of Amlodipine Pretreatment on Contrast-Induced Acute Kidney Injury And Overall Survival In Hypertensive Patients.FRONTIERS IN PHARMACOLOGY, 2020
[29]Yin, WJ (Yin, Wenjun), G (Zhou, Ge), Zhou, LY (Zhou, Lingyun), MC (Liu, Mancang), Xie, YL (Xie, Yueliang), Wang, JL (Wang, Jianglin), Zuo, SR (Zuo, Shanru), Liu, K (Liu, Kun), Hu, C (Hu, Can), Chen, LH (Chen, Linhua), Yang, HQ (Yang, Huiqin).Validation of pre-operative risk scores of contrast-induced acute kidney injury in a Chinese cohort.BMC NEPHROLOGY, 2020
[30]Hu, C (Hu, Can), Li, DY (Li, Daiyang), Yin, WJ (Yin, Wenjun).Evaluation of cystatin C-derived glomerular filtration rate equations in Chinese population.SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2019
[31]Zou, C (Zou, Chan), Huang, J (Huang, Jie), Hua, Y (Hua, Ye), S (Yang, Shuang), XY (Yang, Xiaoyan), Guo, C (Guo, Can), Tan, HY (Tan, Hongyi), Chen, J (Chen, Jun), Chu, ZX (Chu, Zhaoxing), Pei, Q (Pei, Qi), Yang, GP (Yang, Guoping).Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.FRONTIERS IN PHARMACOLOGY, 2019
[32]Liu, K (Liu, Kun), LY (Zhou, Ling-yun), Li, DY (Li, Dai-yang), Cheng, WJ (Cheng, Wen-jing), Yin, WJ (Yin, Wen-jun), Hu, C (Hu, Can), Xie, YL (Xie, Yue-liang), Wang, JL (Wang, Jiang-lin), Zuo, SR (Zuo, Shan-ru), Chen, LH (Chen, Lin-hua), Zhou, G (Zhou, Ge).A novel rat model of contrast-induced nephropathy based on dehydration.JOURNAL OF PHARMACOLOGICAL SCIENCES, 2019
[33]Li, DY (Li, Dai-yang), Yin, WJ (Yin, Wen-jun), Yi, YH (Yi, Yi-hu), Zhang, BK (Zhang, Bi-kui), Zhao, J (Zhao, Jun), Zhu, CN (Zhu, Chao-nan), Ma, RR (Ma, Rong-rong), LY (Zhou, Ling-yun), Xie, YL (Xie, Yue-liang), Wang, JL (Wang, Jiang-lin), Zuo, SR (Zuo, Shan-ru), Liu, K (Liu, Kun), Hu, C (Hu, Can), Zhou, G (Zhou, Ge).New equation to estimate glomerular filtration rate in China: a reference issue reply.KIDNEY INTERNATIONAL, 2019
[34]Li, DY (Li, Dai-Yang), Yin, WJ (Yin, Wen-jun), Yi, YH (Yi, Yi-hu), Zhang, BK (Zhang, Bi-kui), Zhao, J (Zhao, Jun), Zhu, CN (Zhu, Chao-nan), Ma, RR (Ma, Rong-rong), LY (Zhou, Ling-yun), Xie, YL (Xie, Yue-liang), Wang, JL (Wang, Jiang-lin), Zuo, SR (Zuo, Shan-ru), Liu, K (Liu, Kun), Hu, C (Hu, Can), Zhou, G (Zhou, Ge).Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population.KIDNEY INTERNATIONAL, 2019
[35]尹文俊, 周凌云, 李岱阳, 刘昆, 胡灿.Mehran评分在中国人群造影剂肾病风险预测中的有效性分析.东南大学学报(医学版), 2018
[36]Zhou, LY (Zhou, Ling-Yun), Yang, SF (Yang, Shuo-Fei), Z (Zhang, Zhen), Zhang, C (Zhang, Chi), Shen, L (Shen, Long), Gu, ZC (Gu, Zhi-Chun).A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation.FRONTIERS IN PHYSIOLOGY, 2018
[37]Hu, C (Hu, Can), Yin, WJ (Yin, Wen-jun), Li, DY (Li, Dai-yang), Ding, JJ (Ding, Jun-jie), LY (Zhou, Ling-yun), Wan, JL (Wan, Jiang-lin), Ma, RR (Ma, Rong-rong), Liu, K (Liu, Kun), Zhou, G (Zhou, Ge).Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018
[38]Li, DY (Li, Dai-Yang), Yin, WJ (Yin, Wen-Jun), LY (Zhou, Ling-Yun), Ma, RR (Ma, Rong-Rong), Liu, K (Liu, Kun), Hu, C (Hu, Can), Zhou, G (Zhou, Ge).Utility of cystatin C-based equations in patients undergoing dialysis.CLINICA CHIMICA ACTA, 2018
[39]Guan, XF (Guan, Xiao-feng), Li, DY (Li, Dai-yang), Yin, WJ (Yin, Wen-jun), Ding, JJ (Ding, Jun-jie), Zhou, LY (Zhou, Ling-yun), Wang, JL (Wang, Jiang-lin), Ma, RR (Ma, Rong-Rong).Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients.EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018

total39 2/2

first previousnextlast Page